>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
不同病理分期和分子分型的乳腺癌患者行ARM后水肿发生率的相关性研究
作者:汪海仪1  夏飞1  吴宝潮1  王筝2 
单位:1. 铜陵市人民医院 甲乳外科, 安徽 铜陵 244000;
2. 铜陵市人民医院 血管科, 安徽 铜陵 244000
关键词:分子分型 病理分期 乳腺癌 ARM技术 淋巴水肿 
分类号:R737.9
出版年·卷·期(页码):2018·37·第四期(607-611)
摘要:

目的:探讨反向腋窝淋巴结示踪(axillary reverse mapping,ARM)后乳腺癌患者上肢淋巴水肿情况与不同病理分期和分子分型之间的相关性。方法:所有乳腺癌患者术中行腋窝淋巴结清扫术(ALND)+ARM术,以亚甲蓝为示踪剂,术后分析不同的病理分期和不同的分子分型患者间的上肢水肿情况。结果:依据病理分期分组和分子分型分组的病例术前基线资料比较差异无统计学意义。病理分期组间水肿发生情况差异有统计学意义(χ2=21.081,P<0.05);分子分型组间水肿发生情况差异也有统计学意义(χ2=6.205,P<0.05)。分期较晚及分子分型为Her2阳性或三阴性乳腺癌的患者术后更容易患上肢淋巴水肿。上肢淋巴水肿组年龄大于50岁和体质量指数大于25 kg·m-2者分别占65.6%(21/32)和73.9%(17/23),显著高于非上肢淋巴水肿组的31.0%(9/29)和34.2%(13/38),组间差异均有统计学意义(均P<0.05)。多因素分析显示,在校正了放射治疗与否、糖尿病及饮酒史后,年龄和体质量指数是乳腺癌治疗相关上肢淋巴水肿的危险因素。结论:乳腺癌患者ARM后上肢淋巴水肿发生情况与患者病理分期和分子分型均具有相关性,对年龄大于50岁和体质量指数大于25 kg·m-2的患者在治疗中应予以高度重视,避免淋巴水肿发生。

Objective:To study the correlation between limb lymphedema and pathological stage and molecular typing in patients with breast cancer after axillary reverse mapping(ARM).Methods:All patients with breast cancer underwent axillary lymph node dissection (ALND)+ARM, methylene blue as a tracer were postoperatively analyzed of different pathological staging and different molecular classification among patients upper limb edema. Results:There were no statistically significant differences in the preoperative baseline data between the pathological staging and the subgroups, respectively, and the groups were comparable(P>0.05). There was a significant difference in the incidence of edema between the two groups of pathological stages (χ2=21.081,P<0.05). There was a significant difference in the incidence of edema between the two groups of molecular typing (χ2=6.205,P<0.05). The patients on late pathological stage or Her2-positive or triple-negative breast cancer were more likely to develop lymphedema. Single factor analysis showed that, in the upper limb lymphedema group, patients older than 50 years of age accounted for 65.6% (21/32) and these with a body mass index greater than 25 kg·m-2 73.9% (17/23), significantly higher than that of non-upper extremity lymphedema group (9/29) and 34.2% (13/38) respectively, the differences between groups were statistically significant (P<0.05). Multivariate analysis showed that age and body mass index were risk factors for upper limb lymphedema after breast cancer treatment after adjusting for radiation therapy, diabetes and drinking history. Conclusion:The decrease of lymphedema by ARM technology in breast cancer patients is correlated with the pathological stage and molecular typing. For patients older than 50 years old and the body mass index greater than 25 kg·m-2, the patients should be highly valued in the treatment to avoid lymphedema.

参考文献:

[1] YANG S E,ZHAO B.Research progress in the use of drugs for breast cancer targeted therapy[J].Chin J Clin Oncol,2008,5(3):320-325.
[2] PASKO J L,GARREAU J,CARL A,et al.Axillary reverse lymphatic mapping reduces patient perceived incidence of lymphedema after axillary dissection in breast cancer[J].Am J Surg,2015,209(5):890-895.
[3] CHANISHVILI N.Bacteriophages as the rapeutic and prophylactic means:summary of the soviet and post soviet experiences[J].Curr Drug Deliv,2016,13(3):309-323.
[4] 周彦君,曹旭晨,陆肖玮.局部晚期乳腺癌患者腋下逆行淋巴造影的可行性及肿瘤学安全性研究[J].中华肿瘤防治杂志,2015(b22):92-93.
[5] 贾苗苗,梁至洁,陈钦.降低乳腺癌术后淋巴水肿新技术——腋窝反向淋巴制图的研究进展[J].中国肿瘤临床,2014,41(3):211-214.
[6] LUITEN E J,BEEK M A,RUBIO I T.Clinical utility of axillary reverse mapping(ARM) in an era of changing perceptions concerning axillary surgery[J].Eur J Surg Oncol,2016,42(5):585-592.
[7] 喻大军,钱军,李靖,等.染料法腋窝反向淋巴作图300例临床研究[J].中国肿瘤临床,2013,40(21):1296-1299.
[8] FAN L,STRASSER-WEIPPL K,LI J J,et al.Breast cancer in China[J].Lancet Oncol,2014,15(7):279-289.
[9] VANDER VORST J R,SCHAAFSMA B E,VERBEEK F P,et al.Randomized comparison of near-infrared fluorescrence imaging using indocyanine green and99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients[J].Ann Surg Oncol,2012,19(13):4104-4111.
[10] von MINCKWITZ G,EIDTMANN H,REZAI M,et al.Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer[J].N Engl J Med,2012,366(5):299-309.
[11] BEEK M A,GOBARDHAN P D,SCHOENMAECKERS E J,et al.Axillary reverse mapping in axillary surgery for breast cancer:an update of the current status[J].Breast Cancer Res Treat,2016,158(3):421-453.
[12] GEBRUERS N,TJALMA W A.Clinical feasibility of axillary reverse mapping and its influence on breast cancer related lymphedema:a systematic review[J].Eur J Obstet Gynecol Reprod Biol,2016,200(3):117-139.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 155013 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232483 83272481
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364